Literature DB >> 15072827

CYP1B1 and CYP19 gene polymorphisms and breast cancer incidence: no association in the ARIC study.

Bharat Thyagarajan1, Marcia Brott, Pamela Mink, Aaron R Folsom, Kristin E Anderson, William Starr Oetting, Myron Gross.   

Abstract

We conducted a nested case control study of 178 incident breast cancer cases and 356 controls in the Atherosclerosis Risk in Communities study. We evaluated the association between breast cancer and Val432Leu polymorphism in the CYP1B1 gene and the tetranucleotide repeats in intron 4 of the CYP19 gene. After adjustment for height, age at menopause, age at menarche, BMI, HRT, and alcohol intake, carriers of the Val/Leu or Val/Val genotype had a 1.45 fold (95% CI 0.85-2.47) greater odds of breast cancer than Leu/Leu carriers. There was no association of the breast cancer with any individual CYP19 allele. Compared to individuals homozygous with the 167 allele, odds ratios were close to 1.0 for the 167 heterozygous genotype and for the remaining tetranucleotide repeats combined. Our data shows no association between breast cancer and the Leu432Val polymorphism of the CYP1B1 gene or the tetranucleotide repeats of the CYP19 gene.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15072827     DOI: 10.1016/j.canlet.2003.12.009

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  13 in total

1.  A comprehensive examination of CYP19 variation and risk of breast cancer using two haplotype-tagging approaches.

Authors:  Janet E Olson; James N Ingle; Cynthia X Ma; Linda L Pelleymounter; Daniel J Schaid; V Shane Pankratz; Robert A Vierkant; Zachary S Fredericksen; Yanhong Wu; Fergus J Couch; Celine M Vachon; Thomas A Sellers; Richard M Weinshilboum
Journal:  Breast Cancer Res Treat       Date:  2006-09-27       Impact factor: 4.872

2.  Association between the CYP1B1 polymorphisms and risk of cancer: a meta-analysis.

Authors:  Jie-Ying Liu; Yu Yang; Zhi-Zhong Liu; Jian-Jun Xie; Ya-Ping Du; Wei Wang
Journal:  Mol Genet Genomics       Date:  2014-12-05       Impact factor: 3.291

3.  Genetic polymorphisms, hormone levels, and hot flashes in midlife women.

Authors:  Chrissy Schilling; Lisa Gallicchio; Susan R Miller; Patricia Langenberg; Howard Zacur; Jodi A Flaws
Journal:  Maturitas       Date:  2006-12-21       Impact factor: 4.342

4.  Association of CYP1B1 Polymorphisms with Breast Cancer: A Case-Control Study in the Han Population in Ningxia Hui Autonomous Region, P. R. China.

Authors:  Haiyan Jiao; Chunlian Liu; Weidong Guo; Liang Peng; Yintao Chen; Francis L Martin
Journal:  Biomark Insights       Date:  2010-02-12

5.  A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole.

Authors:  Zaida Garcia-Casado; Angel Guerrero-Zotano; Antonio Llombart-Cussac; Ana Calatrava; Antonio Fernandez-Serra; Amparo Ruiz-Simon; Joaquin Gavila; Miguel A Climent; Sergio Almenar; Jose Cervera-Deval; Josefina Campos; Carlos Vazquez Albaladejo; Antonio Llombart-Bosch; Vicente Guillem; Jose A Lopez-Guerrero
Journal:  BMC Cancer       Date:  2010-02-09       Impact factor: 4.430

6.  Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors.

Authors:  Liewei Wang; Katarzyna A Ellsworth; Irene Moon; Linda L Pelleymounter; Bruce W Eckloff; Yvette N Martin; Brooke L Fridley; Gregory D Jenkins; Anthony Batzler; Vera J Suman; Saranya Ravi; J Michael Dixon; William R Miller; Eric D Wieben; Aman Buzdar; Richard M Weinshilboum; James N Ingle
Journal:  Cancer Res       Date:  2010-01-01       Impact factor: 12.701

7.  The (TTTA)n polymorphism in intron 4 of CYP19 and the polycystic ovary syndrome risk in a Chinese population.

Authors:  P Xu; X L Zhang; G B Xie; C W Zhang; S M Shen; X X Zhang; Y X Cao; W J Wang; Y N Che; Y J Xia; X K Wu; L Yi; Q Gao; Y Wang
Journal:  Mol Biol Rep       Date:  2013-05-10       Impact factor: 2.316

8.  Shu-Gan-Liang-Xue Decoction Simultaneously Down-regulates Expressions of Aromatase and Steroid Sulfatase in Estrogen Receptor Positive Breast Cancer Cells.

Authors:  Xue-Song Fu; Ping-Ping Li
Journal:  Chin J Cancer Res       Date:  2011-09       Impact factor: 5.087

9.  Genetic variation in CYP19A1 and risk of breast cancer and fibrocystic breast conditions among women in Shanghai, China.

Authors:  Chu Chen; Lori C Sakoda; Jennifer A Doherty; Melissa M Loomis; Sherianne Fish; Roberta M Ray; Ming Gang Lin; Wenhong Fan; Lue Ping Zhao; Dao Li Gao; Helge Stalsberg; Ziding Feng; David B Thomas
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-12       Impact factor: 4.254

10.  The discrepancy of aromatase expression in epicardial adipose tissue between CHD and non-CHD patients.

Authors:  Yifan Li; Weiwei Cheng; Bin Zhao; Dongliang Ma; Xing Wei; Shunye Zhang
Journal:  Cardiovasc J Afr       Date:  2021-06-07       Impact factor: 1.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.